Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | PARP1 | P09874 | 5/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.58 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716404 | 1.00 | KMT2A (0.71) | KMT2AMEN1L3MBTL1PARP1PARP10 | |
| SCHEMBL3362788 | 0.87 | MEN1 (0.77) | KMT2AMEN1L3MBTL1PARP1PARP10 | |
| SCHEMBL18671651 | 0.86 | KMT2A (0.87) | KMT2AMEN1L3MBTL1PARP1PARP10 | |
| SCHEMBL5820518 | 0.86 | L3MBTL1 (0.73) | KMT2AMEN1L3MBTL1RAB9APOLB | |
| SCHEMBL11545396 | 0.85 | PARP1 (0.74) | KMT2AMEN1L3MBTL1PARP1PARP10 | |
| SCHEMBL10964661 | 0.85 | L3MBTL1 (0.77) | KMT2AMEN1L3MBTL1RAB9APOLB | |
| Benzamide SCHEMBL27225883 | 0.85 | ALDH1A1 (0.68) | KMT2AMEN1L3MBTL1PARP1RAB9A | |
| SCHEMBL11803436 | 0.85 | L3MBTL1 (0.71) | KMT2AMEN1L3MBTL1RAB9APOLB | |
| SCHEMBL3646401 | 0.85 | MEN1 (0.73) | KMT2AMEN1L3MBTL1PARP1PARP10 | |
| SCHEMBL10970617 | 0.84 | RAB9A (0.85) | KMT2AMEN1L3MBTL1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-07-10 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-5719151-A | PHTHALAZINEDIONE COMPOUND; POLYMERASE INHIBITOR | SHALL SYDNEY (GB) | 1998-02-17 | — | — | US | disclosed |
| US-5633282-A | ENZYME INHIBITORS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
| EP-0531370-B1 | INHIBITION OF VIRAL INFECTION | BRITISH TECH GROUP (GB) | 1996-09-18 | — | — | EP | disclosed |
| EP-0531370-A1 | INHIBITION OF VIRAL INFECTION. | COLLINS MARY KATHARINE LEVINGE (GB) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991018591-A1 | INHIBITION OF VIRAL INFECTION | COLLINS MARY KATHARINE LEVINGE (GB) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | KMT2A 3895/4885MEN1 3515/4885L3MBTL1 4251/4885 |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | KMT2A 646/4885MEN1 2421/4885L3MBTL1 4630/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KMT2A 792/4885MEN1 647/4885L3MBTL1 3309/4885 |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | KMT2A 646/4885MEN1 2421/4885L3MBTL1 4630/4885 |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | KMT2A 1233/4885MEN1 4779/4885L3MBTL1 3713/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | KMT2A 4034/4885MEN1 3859/4885L3MBTL1 4245/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | KMT2A 646/4885MEN1 2421/4885L3MBTL1 4630/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | KMT2A 3895/4885MEN1 3515/4885L3MBTL1 4251/4885 |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | KMT2A 646/4885MEN1 2421/4885L3MBTL1 4630/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | KMT2A 3895/4885MEN1 3515/4885L3MBTL1 4251/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | KMT2A 646/4885MEN1 2421/4885L3MBTL1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.